IN VIVO GENOTOXICITY ASSAYS

ANDREAS HARTMANN,[1] KRISTA L. DOBO,[2] AND HANS-JÖRG MARTUS[1]
[1]*Novartis Pharma AG, Basel, Switzerland*
[2]*Pfizer Global R&D, Groton, Connecticut*

Contents

1 INTRODUCTION

The preclinical safety assessment of drug candidates includes conduct of assays intended to identify genotoxic hazards. Experience with genetic toxicology testing over the past several decades has demonstrated that no single assay is capable of detecting all genotoxic effects. Therefore, the potential for a chemical to cause genotoxicity is typically determined through a battery of tests conducted *in vitro* and *in vivo*. Genotoxicity tests are typically conducted early in the development of

Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development, and Manufacturing
Edited by Shayne C. Gad